Oslo Cancer Cluster member Immunitrack has landed investments worth millions. The money will be used to develop a computer program that can predict how the immune system will react to different substances.
Already Immunitrack, co-founded by Stephan Thorgrimsen and Sune Justesen, is offering contracted research to the pharmaceutical industry predicting how the immune system react to different pharmaceuticals, by producing reagents that can be used to examine the immune systems reaction.
New AI in The Making
When scientists discover promising substances they think can be developed into medicine for future treatments, only a small percentage will prove to have an effect after testing. The testing process is important, but at the same time expensive, time and resource consuming. What if a lot of this testing could be done virtually by a computer program? This is what Immunitrack want to offer with their new AI- technology.
The new investment will take this further and enable the company to boost its production and analytical capabilities. The investment will enable increased efforts in the development of a new best in class Prediction Software using artificial intelligence (AI). The software is seen as a vital cornerstone for applying the technology from Immunitrack in large scale projects within cancer treatment and precision medicine.
The applications of the new AI platform are multiple: The technology increases vaccine potency, speeds up the development of personalized cancer vaccines and remove negative immunological effects. Additionally, it enhances precision medicine efforts by improving patient profiling and treatment selection.
And everything is really moving fast for Immunitrack.
— Until September last year it was only the two of us that stood for everything. Production, marketing, you name it. Then things started happening for real and now we have employed 4 new colleagues, says Stephan Thorgrimsen.
The new investment is from Blenheim Capital Limited. They are a diversified investment company focusing on geographically, commercially and technologically frontier companies and projects.
The investment in Immunitrack ApS with its emphasis on transforming market proven immunology-based skill set into a commercially viable AI solution matches Blenheim’s investment profile.
Immunitrack aims at becoming a world leader within prediction and assessment of biotherapeutic impact on patient immune response. The company has until now provided services and reagents to more than 70 biotech companies worldwide, including 6 of the top 10 Pharma companies.
Immunitrack was founded in 2013 by Sune Justesen and Stephan Thorgrimsen. Sune Justesen brings in experience from more than a decade of working in one of the world leading research groups at the University of Copenhagen. The company started commercialization of its products in 2016, and has grown its staff from 2 to 6 within the last 8 months.